3/4
06:06 am
annx
Annexon Spotlights GA Phase III, GBS Regulatory Plans and ANX1502 Update at TD Cowen Conference [Yahoo! Finance]
Medium
Report
Annexon Spotlights GA Phase III, GBS Regulatory Plans and ANX1502 Update at TD Cowen Conference [Yahoo! Finance]
2/24
08:00 am
annx
Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference
Low
Report
Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference
2/17
08:21 am
annx
Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy [Yahoo! Finance]
Low
Report
Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy [Yahoo! Finance]
2/17
08:00 am
annx
Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy
Low
Report
Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy
1/24
02:16 am
annx
Annexon Offers A High-Risk, High-Reward Play On A New Approach To Complement-Mediated Diseases [Seeking Alpha]
Low
Report
Annexon Offers A High-Risk, High-Reward Play On A New Approach To Complement-Mediated Diseases [Seeking Alpha]
1/23
05:05 am
annx
Annexon (NASDAQ:ANNX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Annexon (NASDAQ:ANNX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/18
10:21 am
annx
Assessing Annexon (ANNX) Valuation After EMA Filing For Tanruprubart In Guillain Barre Syndrome [Yahoo! Finance]
Low
Report
Assessing Annexon (ANNX) Valuation After EMA Filing For Tanruprubart In Guillain Barre Syndrome [Yahoo! Finance]
1/16
05:05 pm
annx
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
1/14
05:26 pm
annx
Annexon Maps “Pivotal” 2026 at JPM Conference: ANX007 Phase 3 GA Readout, ANX005 Filings Ahead [Yahoo! Finance]
Medium
Report
Annexon Maps “Pivotal” 2026 at JPM Conference: ANX007 Phase 3 GA Readout, ANX005 Filings Ahead [Yahoo! Finance]
1/14
08:42 am
annx
Annexon (NASDAQ:ANNX) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
High
Report
Annexon (NASDAQ:ANNX) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
1/12
07:00 am
annx
Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026
Medium
Report
Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026
1/8
08:00 am
annx
Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome
Medium
Report
Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome
1/7
04:23 pm
annx
Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Medium
Report
Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/7
04:05 pm
annx
Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
12/24
06:15 am
annx
Annexon (NASDAQ:ANNX) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.
Low
Report
Annexon (NASDAQ:ANNX) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.
12/23
07:01 am
annx
Annexon (NASDAQ:ANNX) was given a new $16.00 price target on by analysts at Chardan Capital.
Medium
Report
Annexon (NASDAQ:ANNX) was given a new $16.00 price target on by analysts at Chardan Capital.
12/16
07:31 pm
annx
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)